These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
5. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
6. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Gotto AM Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232 [TBL] [Abstract][Full Text] [Related]
8. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Shapiro MD; Fazio S Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970 [TBL] [Abstract][Full Text] [Related]
9. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472 [TBL] [Abstract][Full Text] [Related]
10. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Raggi P; Genest J; Giles JT; Rayner KJ; Dwivedi G; Beanlands RS; Gupta M Atherosclerosis; 2018 Sep; 276():98-108. PubMed ID: 30055326 [TBL] [Abstract][Full Text] [Related]
11. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Hafiane A; Daskalopoulou SS Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900 [TBL] [Abstract][Full Text] [Related]
12. Inflammation in atherosclerosis: transition from theory to practice. Libby P; Okamoto Y; Rocha VZ; Folco E Circ J; 2010 Feb; 74(2):213-20. PubMed ID: 20065609 [TBL] [Abstract][Full Text] [Related]
13. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation. Zhang RS; Weber BN; Araiza-Garaygordobil D; Garshick MS Curr Cardiol Rep; 2024 May; 26(5):423-434. PubMed ID: 38573553 [TBL] [Abstract][Full Text] [Related]
14. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. van Diepen JA; Berbée JF; Havekes LM; Rensen PC Atherosclerosis; 2013 Jun; 228(2):306-15. PubMed ID: 23518178 [TBL] [Abstract][Full Text] [Related]
15. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445 [TBL] [Abstract][Full Text] [Related]
16. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Ridker PM Cardiovasc Res; 2021 Sep; 117(11):e138-e140. PubMed ID: 34352102 [No Abstract] [Full Text] [Related]
17. Targeting inflammation in cardiovascular diseases. still a neglected field? Gómez-Guerrero C; Mallavia B; Egido J Cardiovasc Ther; 2012 Aug; 30(4):e189-97. PubMed ID: 21884009 [TBL] [Abstract][Full Text] [Related]